ClinicalTrials.gg
CompletedNCT00240812Updated Jun 29, 2011

A Study to Determine if Ibuprofen in Combination With Pseudoephedrine HCl is More Effective Than Each Drug Alone in the Treatment of Nighttime Bedwetting

A Phase 2 interventional study of ibuprofen; pseudoephedrine HCl in Enuresis, sponsored by Johnson & Johnson Consumer and Personal Products Worldwide. Completed. Open to participants aged 6 Years to 11 Years. Per ClinicalTrials.gov, last updated 2011-06-29.

Primary conditionNocturnal EnuresisRegistry: EnuresisReclassifiedWhy we changed it
Registry
Enuresis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Nocturnal Enuresis
Why
  1. The registry often attaches Enuresis to studies about something else, and this study's title and listed conditions do not name it.
  2. The study's title name Nocturnal Enuresis, a narrower term within Enuresis.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Johnson & Johnson Consumer and Personal Products Worldwide (formerly part of Johnson & Johnson) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
318
Allocation
Randomized
Ages
6 Years to 11 Years
Sex
All
01

Study summary

The purpose of the study is to determine if ibuprofen in combination with pseudoephedrine HCl in the treatment of nightime bedwetting in children is more effective than each drug alone and if the individual drugs are more effective than placebo.

Read the detailed description

The objective of this double-blind, placebo-controlled, randomized, parallel-group study is to determine whether the effectiveness of ibuprofen in combination with pseudoephedrine HCl is greater than the individual drugs alone and greater than placebo for the treatment of nighttime bedwetting in children. After a screening visit, parents of eligible patients are to record in a diary, the number of urinations and wet and dry nights. Patients then return and those who continue to be eligible are randomized to study medication, which they will take for two weeks. Patients are randomized into four treatment groups, and the dose of treatment medication is determined based on body weight. The four treatment groups are: 12.5 mg of ibuprofen suspension/kg of body weight (200-450 mg of ibuprofen) plus 15 mg or 30 mg of pseudoephedrine HCl, 12.5 mg of ibuprofen suspension / kg of body weight (200 - 450 mg of ibuprofen) plus placebo suspension, or two doses of placebo suspension. The primary efficacy measurement is the mean reduction in wet nights, for the 14-day baseline period to the 14-day treatment period. Safety assessments consist of monitoring adverse events, physical examination and assessment of vital signs. The study hypothesis is that ibuprofen in combination with pseudoephedrine HCl has a greater effect in the treatment of nighttime bedwetting than either ibuprofen or pseudoephedrine HCl alone, and the combination is well tolerated. Treatment medication are an oral suspension, expressed as mg/kg body weight. Patients will receive 1 of 4 treatments for 2 weeks: ibuprofen (12.5 mg/kg of body weight) plus 15 or 30 mg of pseudoephedrine, ibuprofen (12.5 mg/kg of body weight) + placebo, 15 or 30 mg of pseudoephedrine, or placebo

02

Conditions studied

  • Enuresis

Browse trials for

Keywords

  • nocturnal enuresis
  • bedwetting
  • ibuprofen
03

In context

Nocturnal Enuresis Reclassified

105 studies on the registry are indexed under Nocturnal Enuresis; 22 are open to participants now.

This study's enrollment of 318 is above the median of 66 across 77 interventional studies indexed under Nocturnal Enuresis.

Browse Nocturnal Enuresis studies →

Lead sponsor

Johnson & Johnson Consumer and Personal Products Worldwide is the lead sponsor of 60 studies on the registry; none are open to participants now.

First submitted before Johnson & Johnson Consumer and Personal Products Worldwide left Johnson & Johnson.

Compared within Nocturnal Enuresis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Enuresis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
6 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject has nighttime bedwetting
  • between the 5th and 95th percentiles for weight based on age and gender
  • has a minimum of eight wet nights per 14 days of the baseline period
  • healthy with no symptoms of any other complicating disease as determined by medical history review, physical examination, and clinical laboratory tests.

Exclusion criteria

Exclusion Criteria:

  • Subject has daytime urinary incontinence or abnormal bowel habits (i.e. fecal incontinence or constipation)
  • has had episodes of dryness lasting one month or longer, at any time in the past
  • has a medical condition which may be relevant to participation in the study
  • has a known sensitivity or allergy to the study medications.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
318 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. The mean reduction in wet nights from the 14-day baseline period to the 14-day treatment period.

Secondary outcomes

  1. The proportion of subjects with at least a 50% reduction in wet nights from baseline; the mean number of wet nights during the 14 days of treatment.

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Caldwell PH, Codarini M, Stewart F, Hahn D, Sureshkumar P. Alarm interventions for nocturnal enuresis in children. Cochrane Database Syst Rev. 2020 May 4;5(5):CD002911. doi: 10.1002/14651858.CD002911.pub3. PubMed 32364251 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 29, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00240812
First posted
Oct 18, 2005
Completion
Nov 2002
Last update
Jun 29, 2011

Study contacts

McNeil Consumer & Specialty Pharmaceuticals, a Division of Mc Neil-PPC, Inc. Clinical Trial
study director · McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ibuprofen · Pseudoephedrine

Start the discussion